Philadelphia, PA, Tuesday, February 09, 2016: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) announced today that it is beginning to consider study designs for potential tests of the activity and potential uses of its natural alpha interferon (Alferon® N and Alferon® LDO) and rintatolimod (Ampligen®) drug formulations against the Zika virus. The …